Immunome (Nasdaq: IMNM) presented preclinical data on Oct. 23, 2025 showing its proprietary ADC payload HC74 overcomes several ADC resistance mechanisms, including payload efflux and target heterogeneity.The poster reported HC74 is a novel topoisomerase I inhibitor used in IM-1021 (a ROR1-targeted ADC in Phase 1) and in multiple preclinical candidates; key findings include high membrane permeability, robust bystander activity, and efficacy in preclinical models refractory or resistant to trastuzumab-DXd, irinotecan, and models with heterogeneous target expression.A copy of the poster is available in the company’s Events & Presentations materials.

Scientific Reports - Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy

Get more from THE OPTIONS BULLY on Patreon

Rhumbline Advisers boosted its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 30.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 88,888 shares of the company’s stock after purchasing an additional 20,721 shares during the period. Rhumbline Advisers owned about 0.10% […]

Zilucoplan TFA (RA101495) is a 15–amino acid macrocyclic peptide and a potent C5 inhibitor. Widely used in studies of complement-mediated disorders, including immune-mediated necrotising myopathy (IMNM), Zilucoplan TFA is manufactured under GMP conditions and verified at high purity. For research use only.(Please contact our staff to place an order or learn about product wholesale prices, specifications, uses and lists)

Dear Patient Community Member, Your voice matters. People living with myositis diseases (& their loved ones) MUST help decide what research gets funded in myositis diseases. The MIHRA Patient Advis...

Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, reported its Q2 2025 financial results and pipeline updates. The company's cash position of $268.0 million is expected to fund operations into 2027.Key pipeline developments include: varegacestat's upcoming Phase 3 RINGSIDE topline data expected by end of 2025 and recent European Medicines Agency Orphan Drug Designation; IM-1021's ongoing Phase 1 trial reaching its third dose level; and IM-3050's IND clearance with Phase 1 trial initiation planned for late 2025. Three additional preclinical ADCs (IM-1617, IM-1340, and IM-1335) are undergoing IND-enabling work.Q2 2025 financials showed R&D expenses of $40.5 million and G&A expenses of $10.0 million, with a net loss of $43.4 million.

YouTube video by hr-Bigband – Frankfurt Radio Big Band

Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. “Immunome continued to build momentum in the first quarter of 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer.“...

The market as measured by the S&P 500 shed 1.53% last month. The dollar was down, gold up. There seems […]